Compare First Trust NASDAQ 100 Technology Index Fund (QTEC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ 100 Technology Index Fund vs Vertex Pharmaceuticals Incorporated — how do they compare? First Trust NASDAQ 100 Technology Index Fund trades at $310.91, while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). Which is the better fit depends on your goals.
| QTEC | VRTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $335.74 | $557.96 |
52-Week Low | $207.03 | $376.62 |
Market Cap | — | $134.06B |
Enterprise Value | — | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QTEC trades at $311.57, down 0.22% with neutral technical signals. The ETF shows bearish moving averages but neutral oscillators, with key support at $310 and resistance at $313. Recent coverage highlights its equal-weighted tech exposure and liquidity advantages over peers like RSPT, with software appearing undervalued relative to historical averages according to Seeking Alpha analysis.
The technology sector ETF offers diversified exposure but faces typical sector volatility risks. Current technical positioning suggests limited near-term momentum, while fundamental analysis indicates selective value opportunities within the portfolio components. Market sentiment remains balanced between growth potential and valuation concerns in the tech space.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
